Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2011

View Archived Issues

Sinovac Biotech obtains GMP certificate in Mexico for two vaccines

Takeda antioxidant response element activator shows promise in experimental colitis

CHDI Foundation discloses new kynurenine 3-monooxygenase inhibitors

Hungarian company presents novel agents for tuberculosis

New agent exploits Warburg effect and shows promise in renal cell cancer models

Acetylon Pharmaceuticals prepares novel HD6 inhibitors

Novel beta-secretase 1 inhibitors synthesized by Amgen

NIH to support studies of Lpath immunotherapy in diabetic neuropathy

New voltage-gated sodium channel modulators presented by GSK

Primary endpoints met in phase III trial of Hisamitsu Pharmaceutical oxybutynin formulation

NexBio reports data from phase II trial of DAS-181

Omthera Pharmaceuticals begins phase III ESPRIT trial

Pulmatrix secures funding for COPD and CF programs

NanoViricides' lead HIVCide shows sustained anti-HIV effects in animal study

FDA extends review of Regeneron's BLA for Eylea

FDA approved new strengths of Lupron Depot-PED allowing administration every 3 months

Nabi Biopharmaceuticals receives another milestone payment from Fresenius

Genetically altered T cells eradicate chronic lymphocytic leukemia cells in patients

New compounds reported for hepatitis C

PharmAthene receives Department of Defense contract for nerve agent medical countermeasure program

Kuros Biosurgery advances European trial of dural sealant KUR-023

Clavis reports interim results from phase II trial of elacytarabine/idarubicin combination

Rhythm Pharmaceuticals begins phase I study in diabetic gastroparesis

Qiagen and Pfizer collaborate on companion diagnostic for investigational lung cancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...